Literature DB >> 20396887

Relay NBS graft with the plus delivery system to improve deployment in aortic Arch with small radius curve.

Carlo Ferro1, Umberto G Rossi, Sara Seitun, Andrea Guastavino, Flavio Scarano, Gian Carlo Passerone.   

Abstract

The purpose of this report is to describe deployment of the Relay NBS Thoracic Stent Graft with the Plus Delivery System (Bolton Medical, Sunrise, FL) in a flexible resin arch model with a 15-mm radius curve as well as our preliminary clinical results. The Relay NBS graft with the Plus Delivery System was evaluated by way of bench testing, which was performed with stent grafts with diameters ranging from 24 to 46 mm and lengths ranging from 100 to 250 mm in flexible resin arch models with a 15-mm arch radius of curvature. The deployment sequence was analyzed. The Relay NBS graft with the Plus Delivery System was deployed in two patients, respectively, having a 6.5-cm penetrating aortic ulcer of the proximal third of the descending thoracic aorta and a DeBakey type-I aortic dissection with chronic false lumen dilatation after surgery due to an entry site at the distal thoracic aorta. Bench tests showed proper conformation and apposition of the Relay NBS graft with the Plus Delivery System in the flexible resin model. This stent graft was deployed successfully into the two patients with a correct orientation of the first stent and without early or late complications. The Relay NBS graft with the Plus Delivery System ensures an optimal conformation and apposition of the first stent in the aortic arch with a small radius of curvature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20396887     DOI: 10.1007/s00270-010-9852-8

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  1 in total

1.  Clinical experience with the RELAY NBS PLUS stent-graft for aortic arch pathology.

Authors:  Junji Yunoki; Toru Kuratani; Yukitoshi Shirakawa; Kei Torikai; Kazuo Shimamura; Keiwa Kin; Yoshiki Sawa
Journal:  Surg Today       Date:  2014-02-06       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.